ROR1 Antibody-Drug Conjugate Linker Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-ROR1 antibody-drug conjugates face issues with linker stability and toxicity due to prone connector exchange and sensitivity to light and acidic conditions, leading to reduced efficacy and increased toxicity in treating cancers with high ROR1 expression.
Innovation Solution
A humanized ROR1 antibody-drug conjugate with a specific structure Ab-[M-L-E-D]x, featuring a better drug-to-antibody ratio and using a cytotoxic drug linked through a stable connector, such as Val-Cit, to target ROR1-positive cancers like colon, gastric, breast, lung, and lymphoma cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional linkers (e.g., maleimide connector) are used in anti-ROR1 ADCs, then the conjugation process is simple, but the linker is prone to exchange with thiol through retro-Michael reaction under physiological conditions, resulting in reduced efficacy and increased toxicity
Solution Approach 1:
The patent changes the chemical parameters of the linker by replacing the maleimide connector with a novel connector containing a cyclic carbonyl group and a nitrogen-containing six-membered ring. This structural modification fundamentally alters the chemical stability properties, preventing the retro-Michael reaction while maintaining conjugation capability. The new connector structure has different electronic and steric properties that confer enhanced stability under physiological conditions.
Solution Approach 2:
The patent creates a composite linker structure combining multiple functional elements: a cyclic carbonyl group, a nitrogen-containing six-membered ring, and specific substituent patterns. This composite molecular design integrates the benefits of different chemical moieties to achieve both stable conjugation and resistance to degradation pathways, resolving the contradiction between ease of manufacture and reliability.
2Ease of operation
If existing ADC formulations are used, then the treatment can be administered, but the drugs are sensitive to light and acidic conditions, leading to decreased stability and increased toxicity
Solution Approach 1:
The patent introduces a novel connector as an intermediary element between the antibody and the cytotoxic drug. This connector acts as a protective mediator that shields the drug from degradation by light and acidic conditions. The cyclic carbonyl group and nitrogen-containing ring structure in the connector provide steric and electronic protection, preventing direct exposure of the drug to harmful environmental factors while maintaining the ADC's therapeutic function.
3Ease of manufacture
If non-specific coupling methods are used, then the preparation process is simple, but the drug-to-antibody ratio is suboptimal, reducing treatment efficacy
Solution Approach 1:
The patent applies local quality modification by introducing site-specific conjugation points on the antibody molecule. Instead of non-specific coupling, the novel connector is designed to attach at predetermined locations on the antibody, creating localized regions of high drug density. This approach maintains manufacturing simplicity while achieving optimal drug-to-antibody ratios through controlled, localized conjugation rather than random distribution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody-drug conjugate demonstrates excellent binding activity and targeted killing effects on ROR1-positive cancers with improved stability and reduced toxicity, enhancing treatment efficacy for cancers with high ROR1 expression.
Implementation Method 1
a humanized ROR1 antibody, which has excellent binding activity to ROR1-positive cells
Implementation Method 2
the antibody (e.g., monoclonal antibody) can specifically recognize a specific target on the surface of a cancer cell, and then guides the ADC to the surface of the cancer cell, and enters the cancer cell through endocytosis effect
Data Source
AI summary
Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).